BRIEF — Lilly's Verzenios nabs EU approval

US pharma major Eli Lilly has received marketing authorization (MA) from the European Commission for for Verzenios (abemaciclib) for the treatment of metastatic breast cancer.

The oral CDK4 and CDK6 inhibitor has been approved to treat women with hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

The MA announcement follows the positive Committee for Medicinal Products for Human Use (CHMP) opinion published in July of this year.

Verzenios was approved in the USA for certain breast cancers in September of 2017.